Global Information
회사소개 | 문의

마이크로바이옴의 각종 제휴 계약 : 계약 조건 및 합의 내용

Global Microbiome Partnering 2012-2018

리서치사 Current Partnering, a division of Wildwood Ventures Limited
발행일 2018년 10월 상품 코드 712892
페이지 정보 영문 126 Pages
가격
US $ 1,995 ₩ 2,290,200 PDF by E-mail (Single User License)
US $ 2,995 ₩ 3,438,200 PDF by E-mail (Multi User License - 2 to 5 Users)
US $ 5,995 ₩ 6,882,200 PDF by E-mail (Multi User Site License - 6+ Users)
US $ 9,995 ₩ 11,474,200 PDF by E-mail (Global License)


마이크로바이옴의 각종 제휴 계약 : 계약 조건 및 합의 내용 Global Microbiome Partnering 2012-2018
발행일 : 2018년 10월 페이지 정보 : 영문 126 Pages

한글목차

마이크로바이옴(Microbiome)에 관련된 최근의 각종 제휴 계약에 대해 조사했으며, 최근의 경향과 동향, 제휴 계약을 활발하게 맺고 있는 기업, 주요 대규모 계약, 각종 제휴 계약의 거래액·계약 유형·기술 구분·합의 내용·목적·조건 등의 각종 데이터를 정리하여 전해드립니다.

주요 요약

제1장 서론

제2장 마이크로바이옴의 각종 계약 동향

  • 서론
  • 과거 몇 년간의 제휴 동향
  • 제휴 계약을 활발하게 맺고 있는 기업
  • 제휴 계약 동향 : 계약 유형별
  • 제휴 계약 동향 : 치료 영역별
  • 제휴 계약 동향 : 산업 부문별
  • 계약 내용
    • 거래총액
    • 선불금
    • 마일스톤
    • 로열티율

제3장 주요 계약

  • 서론
  • 대형 계약 : 계약액별

제4장 제휴 계약을 활발하게 맺고 있는 기업

  • 서론
  • 제휴 계약을 활발하게 맺고 있는 기업
  • 제휴 계약을 활발하게 맺고 있는 기업 : 기업 개요

제5장 마이크로바이옴 계약 디렉토리

제6장 마이크로바이옴 계약 동향 : 기술 유형별

  • 마이크로바이옴

제7장 제휴 자료 센터

  • 온라인 제휴
  • 제휴 이벤트

부록

LSH 18.10.12

영문목차

The Global Microbiome Partnering Terms and Agreements 2010 to 2018 report provides comprehensive understanding and unprecedented access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Global Microbiome Partnering Terms and Agreements 2010 to 2018 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in Microbiome partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Microbiome partnering contract documents

Top Microbiome deals by value

The Global Microbiome Partnering Terms and Agreements report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Microbiome partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Microbiome technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Microbiome agreements announced in the healthcare sectors, covering:

  • Microbiome
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Penicillin
  • Quinolones
  • Sulfonamides
  • Tetracycline
  • Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
  • This report contains over 200 links to online copies of actual Microbiome deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
  • Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
  • The initial chapters of this report provide an orientation of Microbiome dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Microbiome dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading Microbiome deals since 2010. Deals are listed by headline value, signed by big pharma, most active Microbiome dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in Microbiome dealmaking with a brief summary followed by a comprehensive listing of Microbiome deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
  • Chapter 5 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • Chapter 7 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010. The chapter is organized by specific Microbiome technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • In addition, a comprehensive appendix is provided organized by Microbiome partnering company A-Z, deal type definitions and Microbiome partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • The report also includes numerous tables and figures that illustrate the trends and activities in Microbiome partnering and dealmaking since 2010.
  • In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Microbiome technologies and products.

Report scope

  • Global Microbiome Partnering Terms and Agreements 2010 to 2018 is intended to provide the reader with an in-depth understanding and access to Microbiome trends and structure of deals entered into by leading companies worldwide.

Global Microbiome Partnering Terms and Agreements 2010 to 2018 includes:

  • Trends in Microbiome dealmaking in the biopharma industry since 2010
  • Analysis of Microbiome deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Microbiome deals
  • Access to over 200 Microbiome deal records and contract documents where available
  • The leading antibody deals by value since 2010
  • Most active Microbiome dealmakers since 2010
  • The leading Microbiome partnering resources

In Global Microbiome Partnering Terms and Agreements 2010 to 2018, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Global Microbiome Partnering Terms and Agreements 2010 to 2018 provides the reader with the following key benefits:

  • In-depth understanding of Microbiome deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Microbiome agreements with numerous real life case studies
  • Comprehensive access to over 200 Microbiome deals entered into by the world's biopharma companies, together with real world clause examples and contracts where available
  • Full listing of Microbiome deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading Microbiome deals by value since 2010
  • Identify the most active Microbiome dealmakers since 2010
  • Detailed access to actual Microbiome contracts enter into by the leading fifty big pharma and big biotech companies
  • Insight into the terms included in a Microbiome agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Microbiome dealmaking

  • 2.1. Introduction
  • 2.2. Microbiome partnering over the years
  • 2.3. Most active Microbiome dealmakers
  • 2.4. Microbiome partnering by deal type
  • 2.5. Microbiome partnering by therapy area
  • 2.6. Microbiome partnering by industry sector
  • 2.7. Deal terms for Microbiome partnering
    • 2.7.1 Microbiome partnering headline values
    • 2.7.2 Microbiome deal upfront payments
    • 2.7.3 Microbiome deal milestone payments
    • 2.7.4 Microbiome royalty rates
  • 2.8. The anatomy of an Microbiome deal
  • 2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
  • 2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
  • 2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading Microbiome deals

  • 3.1. Introduction
  • 3.2. Top Microbiome deals by value

Chapter 4 - Most active Microbiome dealmakers

  • 4.1. Introduction
  • 4.2. Most active Microbiome dealmakers
  • 4.3. Most active Microbiome partnering company profiles

Chapter 5 - Microbiome contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Microbiome contracts dealmaking directory

Chapter 6 - Microbiome dealmaking by technology type

  • Microbiome
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Metronidazole
  • Penicillin
  • Quinolones
  • Tetracycline

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Microbiome deals by company A-Z
  • Appendix 2 - Microbiome deals by stage of development
  • Appendix 3 - Microbiome deals by deal type
  • Appendix 4 - Microbiome deals by therapy area
  • Appendix 5 -Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Microbiome partnering since 2010
  • Figure 2: Active Microbiome dealmaking activity sincce 2010
  • Figure 3: Microbiome partnering by deal type since 2010
  • Figure 4: Microbiome partnering by disease type since 2010
  • Figure 5: Microbiome partnering by industry sector since 2010
  • Figure 6: Microbiome deals with a headline value
  • Figure 7: Microbiome deals with an upfront value
  • Figure 8: Microbiome deals with a milestone value
  • Figure 9: Microbiome deals with a royalty rate value
  • Figure 10: Top Microbiome deals by value since 2010
  • Figure 11: Most active Microbiome dealmakers since 2010
  • Figure 12: Microbiome partnering by technology type since 2010
  • Figure 13: Online partnering resources
  • Figure 14: Forthcoming partnering events
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research